Enzymotec Ltd (NASDAQ:ENZY)‘s stock had its “hold” rating reiterated by equities research analysts at Jefferies Group LLC in a report released on Thursday. They presently have a $11.50 target price on the biotechnology company’s stock. Jefferies Group LLC’s target price suggests a potential upside of 3.14% from the company’s current price.

A number of other analysts have also issued reports on ENZY. ValuEngine raised Enzymotec from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Zacks Investment Research raised Enzymotec from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Four research analysts have rated the stock with a hold rating, The stock presently has an average rating of “Hold” and an average target price of $11.50.

Shares of Enzymotec (NASDAQ ENZY) traded down 0.45% during mid-day trading on Thursday, hitting $11.15. The stock had a trading volume of 15,561 shares. The firm has a 50 day moving average of $11.33 and a 200-day moving average of $9.33. Enzymotec has a one year low of $5.20 and a one year high of $12.35. The stock’s market cap is $255.88 million.

Enzymotec (NASDAQ:ENZY) last issued its quarterly earnings results on Wednesday, August 16th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.05 by ($0.15). The firm had revenue of $13.00 million during the quarter, compared to analyst estimates of $12.78 million. Enzymotec had a negative return on equity of 6.78% and a negative net margin of 19.41%. The business’s revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.04 earnings per share. Equities research analysts expect that Enzymotec will post $0.14 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/22/enzymotec-ltd-enzy-rating-reiterated-by-jefferies-group-llc.html.

Several large investors have recently modified their holdings of ENZY. Janus Henderson Group PLC acquired a new stake in shares of Enzymotec in the second quarter worth approximately $2,350,000. State Street Corp boosted its stake in shares of Enzymotec by 1.8% in the second quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock worth $169,000 after acquiring an additional 380 shares during the last quarter. Finally, Osborn Williams & Donohoe LLC acquired a new stake in shares of Enzymotec in the third quarter worth approximately $137,000. 27.98% of the stock is currently owned by hedge funds and other institutional investors.

About Enzymotec

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Receive News & Ratings for Enzymotec Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd and related companies with MarketBeat.com's FREE daily email newsletter.